Kim A. Carmichael, MD published a recent article in the February 2022 issue of Consultant 360 titled, “What Do You Need to Know About GLP-1 Receptors Agonists?”
GLP-1 agonists, otherwise known as glucagon-like peptide 1 agonists, are an important class of medications for patients diagnosed with type 2 diabetes.
As the author and series editor, Carmichael answers various questions on GLP-1 receptor agonists, such as their indications, cardiovascular benefits, microvascular outcomes, benefits for nonalcoholic fatty liver disease (NAFLD), and potential drawbacks.
In conclusion to addressing these questions, Carmichael states that “GLP-1 agonists are valuable agents for treating type 2 diabetes and may be used as first-line agents with or without metformin. They should be strongly considered for individuals with known or high risk for cardiovascular disease,” and “are promising agents for the management of individuals with NAFLD.”